ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1167

A Possible Mechanism Of NLRP3 Inflammasome Hypersensitivity In Cryopyrin-Associated Periodic Syndrome

Sayaka Ito, Chie Tagami, Yukichi Hara and Tetsuo Kubota, Tokyo Medical and Dental University, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoinflammatory Disease, inflammasome activation and innate immunity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: NLRP3 in monocytes and other cell types plays a role in innate immunity as one of the intracellular pathogen recognition receptors, and its mutation is responsible for cryopyrin-associated periodic syndromes (CAPS). Once activated, NLRP3 forms a protein complex called the inflammasome with procaspase-1 and an adaptor protein ASC, leading to activation of caspase-1 and production of mature proinflammatory cytokine IL-1β. Some investigators have proposed a model of NLRP3-inflammasome containing CARD8, another adaptor protein, but the role of CARD8 in the NLRP3-inflammasome system remains obscure. In a previous ACR meeting, we presented some data suggesting that CARD8 normally plays a role as a negative regulator of NLRP3-inflammasome. In the assay system using HEK293 cells transiently transfected with genes for inflammasome components, CARD8 interacted with wild-type NLRP3 resulting in suppression of IL-1β secretion. In contrast, CARD8 did not interact with CAPS-associated mutant NLRP3. Current study aimed to extend the previous study to obtain more convincing data using also cells endogenously expressing components of NLRP3 inflammasome and CARD8.

Methods: HEK293 cells were transiently transfected with ASC, CARD8, procaspase-1, proIL-1β, and NLRP3. The interaction of CARD8 and NLRP3 was studied by immunoprecipitation using lysates of peripheral blood mononuclear cells (PBMCs). Human monocyte-derived macrophages (HMDMs) were obtained by culture of monocytes from peripheral blood cells with GM-CSF for 7 days. Control or specific siRNA against CARD8 was transfected to HMDMs and the knockdown efficacy was evaluated by quantitative RT-PCR. After priming with LPS, HMDMs were stimulated by ATP, and secreted IL-1β was measured by ELISA.

Results: When HEK293 cells were transfected with every inflammasome components, large amounts of IL-1β were secreted spontaneously, which was partially but significantly reduced by coexpression of CARD8. On the other hand, CARD8 did not suppress IL-1β secretion from the cells transfected with CAPS-associated mutant NLRP3 (R260W, D303N, H312P, or N477K). In immunoprecipitation experiments using resting PBMCs from healthy subjects, NLRP3 was precipitated with CARD8, but not with ASC. When PBMCs were primed with LPS followed by ATP stimulation, however, NLRP3 was precipitated with ASC instead of CARD8. By stimulating HMDMs with LPS and ATP, HMDMs secreted IL-1β, and it was further increased by CARD8 knockdown.

Conclusion: These results support our hypothesis that CARD8 normally associates with NLRP3 to prevent unnecessary activation of the inflammasome by subtle stimuli. Taken together with previous data which showed CARD8 was unable to bind to NLRP3 with CAPS-related mutation, one of the mechanisms of hypersensitivity of the NLRP3 inflammasome in CAPS patients might be the escape from CARD8 restriction.


Disclosure:

S. Ito,
None;

C. Tagami,
None;

Y. Hara,
None;

T. Kubota,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-possible-mechanism-of-nlrp3-inflammasome-hypersensitivity-in-cryopyrin-associated-periodic-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology